We passionately believe in the companies we fund and commit ourselves to transforming promising technologies into successful therapies.


Good Therapeutics, founded in 2016 by John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained their platform and the ability to mine it for innovative drugs to fight cancer and other diseases. 


RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex in 2022 for $170 million plus additional milestone payments.


Mirum was founded upon a drug compound that RiverVest helped develop through Lumena, a Fund II company acquired in 2014. After the acquirer deprioritized the drug, the Lumena team bought it back so they could finish what they started — getting kids with rare liver disease the relief they need.


RiverVest co-founded and seed funded Lumena and built a clinical strategy to fast-track its lead drug compound through clinical trials. The company was acquired by Shire in 2014.

rivervest map dots graphic image

RiverVest’s Footprint Increases Its Opportunity Set

St. Louis

101 S. Hanley Road, Suite 1850
St. Louis, MO 63105
Phone: (314) 726.6700

San Diego

10996 Torreyana Road, Suite 280
San Diego, CA 92121
Phone: (314) 726.6700


11000 Cedar Avenue
Cleveland, OH 44106
Phone: (216) 658.3982
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation. Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2024 RiverVest® All Rights Reserved. | Privacy Policy

Subscribe to our newsletter

Rivervest Contact